Thrombotic events after discontinuing dabigatran: rebound or resumption?

BMJ. 2012 Jul 3:345:e4469. doi: 10.1136/bmj.e4469.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged, 80 and over
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Dabigatran
  • Humans
  • Middle Aged
  • Recurrence
  • Thrombosis / etiology*
  • Thrombosis / pathology
  • Thrombosis / prevention & control
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*

Substances

  • Anticoagulants
  • Benzimidazoles
  • beta-Alanine
  • Dabigatran